Una nueva investigación a largo plazo sugiere ahora que el uso de dilatadores totalmente biodegradables es seguro para las arterias del corazón. En un informe que aparece en la edición del 16 de abril de la revista Circulation, investigadores japoneses dijeron que un estudio de diez años ha mostrado que el dilatador biodegradable Igaki-Tamai, fabricado con un material basado en la fécula de maíz, se disuelve en la pared arterial, sin dejar material foráneo permanente en una arteria y reduciendo la ocurrencia de un coágulo sanguíneo dentro del dilatador.
Stryker’s Sustainability Solutions division has announced the launch of Restep, a compression sleeve for deep vein thrombosis treatment.
Mohsen Sharifi, adjunct associate professor of Medicine at A T Still University, Mesa, USA, presented new data demonstrating that percutaneous endovenous intervention (PEVI) is an alternative in the treatment of upper extremity deep vein thrombosis at the iCON meeting in Arizona, USA. Previous studies by Sharifi’s group had demonstrated a successful performance with PEVI in lower extremity deep vein thrombosis.
Results of the EINSTEIN-PE study have shown that the oral anticoagulant rivaroxaban (Xarelto, Janssen and Bayer Healthcare) was comparable to today’s standard of care in treating patients with acute symptomatic pulmonary embolism and in preventing development of venous thromboembolism. The study also found rivaroxaban had a similar safety profile and significantly lower risk of major bleeding versus the current standard regimen. These data were presented as a late breaking clinical trial at the American College of Cardiology Annual Scientific Sessions, and published in the New England Journal of Medicine.
The majority of recurrences following thermal ablation for varicose veins are associated with perforating veins, results of the REVATA study have shown. The investigation involved 164 varicose vein patients who were treated with radiofrequency or endovenous laser ablation.
Guering Eid-Lidt, Department of Interventional Cardiology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, spoke about long-term outcomes of percutaneous mechanical thrombectomy for severe pulmonary embolism at the iCON meeting in Arizona, USA.
For patients with a new synthetic arteriovenous graft for hemodialysis vascular access, taking fish oil every day led to a mix of negative and positive results, a randomized trial showed.
A divided federal appeals court upheld a $371.2 million award in favor of C.R. Bard Inc in a long-running patent infringement dispute with W.L. Gore & Associates over vascular grafts. Reuters.
Cardiovascular Systems (CSI) has announced two new partnerships broadening the company’s product portfolio. According to a company release, CSI is now the exclusive US distributor of OrbusNeich balloon products. Additionally, the company has signed an original equipment manufacturer agreement with Integer Holdings Corporation for CSI-branded ZILIENT guidewires.
The new European Directive laying down basic safety standards for protection against the dangers arising from ionising radiation exposure will come into effect on 6 February 2018. The most relevant change for interventionists in the occupational exposure section is the new annual limit for the lens of the eyes (20 mSv/year, instead of 150 mSv/year), write Eliseo Vano (Madrid, Spain) and Gabriel Bartal (Kfar Saba, Israel).
Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy.
Philips has announced the results of a comprehensive, independent, two-year study demonstrating the clinical workflow benefits of its next generation image-guided therapy platform, Azurion.
The Society of Interventional Radiology (SIR), in coordination with Member of the US House of Representatives (Rep.) from Utah’s 4th district, Mia Love, hosted a panel discussion on the important role of interventional radiologists on trauma teams responding to mass casualty incidents.
Intact Vascular has announced that positive single centre twenty-four month results from its TOBA (Tack optimised balloon angioplasty) clinical study were presented at VEITHsymposium 2017 by Christian Wissgott, assistant director, Westküstenklinikum Heide in Heide, Germany.
Paolo Zamboni, Ferrara, Italy, the proponent of the chronic cerebrospinal venous insufficiency (CCSVI) theory, and his colleagues have reported that the randomised, double-blinded, sham controlled Brave Dreams trial has not demonstrated a benefit for venous angioplasty in the treatment of patients with multiple sclerosis (MS).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos